Humacyte, Inc.(HUMA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HUMA Humacyte, Inc.

盘后交易 09-11 19:57:05 EDT

0.5676

+0.0005

+0.09%

盘后0.5676

+0.00000.00%

19:42 EDT

最高0.5878	最低0.5590	成交量226.50万
今开0.5759	昨收0.5671	日振幅5.08%
总市值1.58亿	流通市值1.39亿	总股本2.78亿
成交额128.59万	换手率0.92%	流通股本2.45亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HUMA","market":"US","secType":"STK","nameCN":"Humacyte, Inc.","latestPrice":0.5676,"timestamp":1789156800000,"preClose":0.5671,"halted":0,"volume":2264981,"hourTrading":{"tag":"盘后","latestPrice":0.5676,"preClose":0.5676,"latestTime":"19:42 EDT","volume":11078,"amount":6292.758198,"timestamp":1789170157537,"change":0,"changeRate":0,"amplitude":0.0074},"delay":0,"changeRate":0.000881678716275692,"floatShares":245000000,"shares":278000000,"eps":-0.497476,"marketStatus":"盘后交易","change":0.0005,"latestTime":"09-11 19:57:05 EDT","open":0.5759,"high":0.5878,"low":0.559,"amount":1285892.4536736999,"amplitude":0.050785,"askPrice":0.59,"askSize":20,"bidPrice":0.5503,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-0.497476,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1789171200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.5671,"preHourTrading":{"tag":"盘前","latestPrice":0.577,"preClose":0.5671,"latestTime":"09:26 EDT","volume":67515,"amount":38799.223134,"timestamp":1789133181535,"change":0.0099,"changeRate":0.017457,"amplitude":0.040381},"postHourTrading":{"tag":"盘后","latestPrice":0.5676,"preClose":0.5676,"latestTime":"19:42 EDT","volume":11078,"amount":6292.758198,"timestamp":1789170157537,"change":0,"changeRate":0,"amplitude":0.0074},"volumeRatio":0.810423,"impliedVol":1.1313,"impliedVolPercentile":0.3625},"requestUrl":"/m/hq/s/HUMA","defaultTab":"news","newsList":[{"id":"1148184945","title":"Humacyte确认与FDA沟通后计划提交Atev透析通路补充生物制剂许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1148184945","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148184945?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:05","pubTimestamp":1787573151,"startTime":"0","endTime":"0","summary":"Humacyte确认，在与美国食品药品监督管理局（FDA）进行讨论后，公司计划提交针对透析通路的Atev补充生物制剂许可申请（sBLA）。这一决定标志着公司在推进关键疗法监管审批道路上迈出了重要一步。据悉，相关申请旨在支持Atev用于透析患者血管通路建立的适应症拓展。公司方面表示，此次沟通为后续提交工作奠定了清晰路径，并有望加速该疗法的临床可及性。业内观察人士指出，这一进展或对终末期肾病患者的治疗选择产生积极影响，同时也反映了Humacyte在再生医学领域的持续深耕。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HUMA","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179362309","title":"Humacyte重磅发布：V007三期血液透析通路试验结果荣登《柳叶刀-数字健康》","url":"https://stock-news.laohu8.com/highlight/detail?id=1179362309","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179362309?lang=zh_cn&edition=full","pubTime":"2026-08-19 20:01","pubTimestamp":1787140872,"startTime":"0","endTime":"0","summary":"Humacyte公司今日宣布，其V007三期血液透析通路临床试验的详细结果已正式发表于国际权威期刊《柳叶刀-数字健康》。该试验旨在评估Humacyte创新的脱细胞组织工程血管在血液透析患者血管通路建立中的安全性与有效性。Humacyte的这一进展，有望在未来重塑肾脏病治疗领域的标准实践，并推动再生医学从实验室走向更广泛的临床应用。业界普遍认为，此次学术发表或将加速该产品在全球主要市场的监管审批进程，对Humacyte的长期战略布局具有深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660419278","title":"RootData：HUMA 将于一周后解锁价值约 942 万美元的代币","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419278","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660419278?lang=zh_cn&edition=full","pubTime":"2026-08-19 11:00","pubTimestamp":1787108406,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据Web3资产数据平台 RootData 代币解锁数据，Huma Finance（HUMA）将于北京时间 08 月 26 日 13 时解锁约 45876 万枚代币，价值约 942 万美元。 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2283677","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176592229","title":"Humacyte宣布FDA受理其全球首个人体临床研究申请，探索Ctev用于冠状动脉搭桥术","url":"https://stock-news.laohu8.com/highlight/detail?id=1176592229","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176592229?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:03","pubTimestamp":1785153802,"startTime":"0","endTime":"0","summary":"Humacyte宣布，美国食品药品监督管理局（FDA）已正式受理其新药临床研究申请（IND），该申请旨在启动一项全球首个人体临床试验，评估其创新产品Ctev在冠状动脉搭桥术（CABG）中的应用。这一里程碑标志着Humacyte在心血管疾病治疗领域迈出关键一步，有望为患者提供更优的血管替代方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146965044","title":"Humacyte 在 V012 三期研究女性透析通路患者中期分析中，Atev 相比标准护理 AV 瘘达到主要优效性终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1146965044","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146965044?lang=zh_cn&edition=full","pubTime":"2026-06-11 04:02","pubTimestamp":1781121738,"startTime":"0","endTime":"0","summary":"在针对女性透析通路患者进行的 V012 三期临床试验中期分析中，Humacyte 的 Atev 达到了相较于标准护理动静脉（AV）瘘的主要优效性终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HUMA","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636788916","title":"RootData：HUMA 将于一周后解锁价值约 1004 万美元的代币","url":"https://stock-news.laohu8.com/highlight/detail?id=2636788916","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636788916?lang=zh_cn&edition=full","pubTime":"2026-05-19 11:00","pubTimestamp":1779159606,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据Web3资产数据平台 RootData 代币解锁数据，Huma Finance（HUMA）将于北京时间 05 月 26 日 13 时解锁约 45876 万枚代币，价值约 1004 万美元。 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2265687","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","HUMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634235580","title":"Huma Finance 旧版 V1 合约遭攻击，约 10.1 万美元 USDC 被盗","url":"https://stock-news.laohu8.com/highlight/detail?id=2634235580","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634235580?lang=zh_cn&edition=full","pubTime":"2026-05-11 23:46","pubTimestamp":1778514360,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据 Huma Finance 官方披露，其在 Polygon 上的旧版 V1 合约遭到漏洞利用，约 101,400 USDC 被转出。项目方表示，本次事件未影响用户资金安全，且 Huma Finance PST 未受影响。其在 Solana 上的 V2 系统为完全重构版本，不受该漏洞影响。Huma 方面称，团队此前已在推进 V1 流动性池逐步下线，目前已全面暂停 V1 相关合约，并将继续处理后续收尾工作。 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2264024","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRCG","CRCA","CRCD","LU1668664300.SGD","CCUP","BK4023","CRCO","LU1861220207.SGD","HUMA","LU0106831901.USD","LU1791807156.HKD","ICRC","LU1861559042.SGD","LU2360107671.USD","LU1861217088.USD","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153284815","title":"Humacyte定于2026年5月13日公布首季度财报并举行业务进展说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1153284815","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153284815?lang=zh_cn&edition=full","pubTime":"2026-05-08 20:00","pubTimestamp":1778241613,"startTime":"0","endTime":"0","summary":"再生医学公司Humacyte, Inc. 宣布，将于2026年5月13日发布其2026财年第一季度的财务业绩报告。\n届时，公司管理层将举行电话会议，不仅详细解读财报关键数据，还将同步介绍公司最新的业务进展与战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HUMA","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107328546","title":"Humacyte与费森尤斯签署经销协议第三次修订案","url":"https://stock-news.laohu8.com/highlight/detail?id=1107328546","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107328546?lang=zh_cn&edition=full","pubTime":"2026-04-24 20:16","pubTimestamp":1777032991,"startTime":"0","endTime":"0","summary":"再生医学公司Humacyte, Inc.于2026年4月21日向美国证券交易委员会提交文件，宣布与全球医疗巨头费森尤斯就双方经销协议达成第三次修订。\n此次修订标志着两家公司在产品商业化战略上的持续深化合作。通过调整经销条款，双方旨在优化市场覆盖效率，加速生物工程组织产品的临床应用推广。\n修订案的具体条款涉及区域分销权重新划分、供应链流程优化以及市场准入策略协同等多维度内容。这一举措凸显了Humacyte对其核心产品商业化进程的战略部署，也反映出费森尤斯对创新医疗技术市场前景的持续看好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171286994","title":"Humacyte斩获Symvess海外独家经销权；费森尤斯将收取低个位数净销售额分成","url":"https://stock-news.laohu8.com/highlight/detail?id=1171286994","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171286994?lang=zh_cn&edition=full","pubTime":"2026-04-24 20:09","pubTimestamp":1777032589,"startTime":"0","endTime":"0","summary":"生物技术公司Humacyte, Inc.宣布获得创新医疗器械Symvess在美国以外市场的独家经销权。根据协议条款，医疗巨头费森尤斯将从该产品的净销售额中获取低个位数百分比的版权费。此次合作将强化Humacyte在全球血管修复领域的商业布局，同时为费森尤斯带来持续性的收入流。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177856021","title":"Humacyte通过重新调整Symvess®海外权利拓展商业与业务发展机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=1177856021","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177856021?lang=zh_cn&edition=full","pubTime":"2026-04-24 20:03","pubTimestamp":1777032228,"startTime":"0","endTime":"0","summary":"Humacyte公司宣布通过对其生物工程血管产品Symvess®在美国以外市场的权利进行战略性重组，进一步拓展全球商业版图与业务发展空间。此次权利调整将优化公司国际资源配置，为未来市场扩张奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","HUMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141450917","title":"Humacyte宣布以色列卫生部受理Symvess®血管创伤修复产品上市授权申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1141450917","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141450917?lang=zh_cn&edition=full","pubTime":"2026-04-21 20:14","pubTimestamp":1776773695,"startTime":"0","endTime":"0","summary":"生物技术公司Humacyte, Inc.近日披露，其针对血管创伤修复的创新产品Symvess®的营销授权申请已正式获得以色列卫生部受理。这一关键进展标志着该产品在以色列市场的监管审批流程迈出重要一步，为潜在的市场准入奠定基础。Symvess®作为一款先进的血管修复解决方案，旨在满足临床对高效、可靠创伤修复技术的迫切需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HUMA","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194424820","title":"Humacyte将于2026年3月27日公布2025年第四季度及全年财务业绩并举行业务说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1194424820","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194424820?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:03","pubTimestamp":1774267398,"startTime":"0","endTime":"0","summary":"生物科技公司Humacyte, Inc.宣布，将于2026年3月27日发布2025财年第四季度及全年财务报告。此次公告将同步披露公司最新业务进展与战略规划。投资者可通过公司官网获取财报详情及电话会议参与方式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HUMA","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123240651","title":"Humacyte公司宣布完成2000万美元普通股定向增发定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1123240651","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123240651?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:33","pubTimestamp":1773923629,"startTime":"0","endTime":"0","summary":"生物技术平台公司Humacyte, Inc.近日宣布与多家新机构投资者达成证券购买协议，将通过定向增发出售2500万股普通股。此次发行由一家新晋生命科学领域专项投资者与一只纯多头共同基金领投，预计总融资规模达2000万美元。交易预计于2026年3月20日左右完成，需满足常规交割条件。相关招股说明书补充文件将提交至SEC官网公布。Titan Partners担任本次发行的独家配售代理。投资者应参阅Humacyte在SEC备案的详细风险披露文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4139","HUMA","BK4232","BK4022","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151319705","title":"Humacyte Inc. 根据销售协议暂停进一步销售，直至提交新招股说明书——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1151319705","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151319705?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:28","pubTimestamp":1773923295,"startTime":"0","endTime":"0","summary":"Humacyte Inc. 已向美国证券交易委员会（SEC）提交文件，宣布将暂停根据其现有销售协议进行的所有进一步销售活动。此项暂停措施将持续至公司向SEC成功提交并生效一份新的招股说明书为止。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HUMA","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195575349","title":"Humacyte在以色列提交Symvess®血管创伤修复产品上市授权申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1195575349","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195575349?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:03","pubTimestamp":1773748993,"startTime":"0","endTime":"0","summary":"生物技术企业Humacyte, Inc.近日宣布，已正式向以色列监管机构递交其创新产品Symvess®的上市授权申请。该产品旨在应用于血管创伤修复领域，标志着公司在全球市场拓展战略中迈出关键一步。若获批，Symvess®将为临床血管重建手术提供全新解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518274962","title":"Humacyte, Inc.盘中异动 急速跳水5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274962","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518274962?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:54","pubTimestamp":1741614878,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时54分，Humacyte, Inc.股票出现异动，股价急速跳水5.02%。Humacyte, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2873.09%、639.16%、148.09%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Dogwood Therapeutics, Inc.，振幅分别为40.24%、28.59%、26.06%。Humacyte, Inc.公司简介：Humacyte Inc 正在开发一个颠覆性的生物技术平台，以提供可普遍植入的生物工程人体组织和器官，旨在改善患者的生活并改变医学实践。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310215439a26a2d90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310215439a26a2d90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HUMA","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517433197","title":"Humacyte, Inc.盘中异动 下午盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517433197","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517433197?lang=zh_cn&edition=full","pubTime":"2025-03-07 04:16","pubTimestamp":1741292182,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日04时16分，Humacyte, Inc.股票出现异动，股价急速下跌5.08%。Humacyte, Inc.股票所在的生物技术行业中，整体跌幅为1.06%。Humacyte, Inc.公司简介：Humacyte Inc 正在开发一个颠覆性的生物技术平台，以提供可普遍植入的生物工程人体组织和器官，旨在改善患者的生活并改变医学实践。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307041622963c8819&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307041622963c8819&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","BK4139","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517607531","title":"Humacyte, Inc.盘中异动 下午盘急速拉升5.07%报3.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517607531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517607531?lang=zh_cn&edition=full","pubTime":"2025-03-05 02:19","pubTimestamp":1741112360,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日02时19分，Humacyte, Inc.股票出现波动，股价大幅上涨5.07%。截至发稿，该股报3.21美元/股，成交量145.081万股，换手率1.13%，振幅7.53%。Humacyte, Inc.股票所在的生物技术行业中，整体跌幅为0.20%。Humacyte, Inc.公司简介：Humacyte Inc 正在开发一个颠覆性的生物技术平台，以提供可普遍植入的生物工程人体组织和器官，旨在改善患者的生活并改变医学实践。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305021920989be2db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305021920989be2db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","BK4139","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516653237","title":"Humacyte, Inc.盘中异动 早盘股价大跌5.29%报3.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653237","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516653237?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:18","pubTimestamp":1741018712,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时18分，Humacyte, Inc.股票出现波动，股价大幅下跌5.29%。截至发稿，该股报3.22美元/股，成交量53.2394万股，换手率0.41%，振幅7.35%。Humacyte, Inc.股票所在的生物技术行业中，整体跌幅为0.42%。Humacyte, Inc.公司简介：Humacyte Inc 正在开发一个颠覆性的生物技术平台，以提供可普遍植入的生物工程人体组织和器官，旨在改善患者的生活并改变医学实践。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304001832a25d6177&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304001832a25d6177&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4563","HUMA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.humacyte.com;investors.humacyte.com","stockEarnings":[{"period":"1week","weight":-0.0485},{"period":"1month","weight":-0.2013},{"period":"3month","weight":-0.4625},{"period":"6month","weight":-0.5111},{"period":"1year","weight":-0.6168},{"period":"ytd","weight":-0.4096}],"compareEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0165},{"period":"3month","weight":0.0217},{"period":"6month","weight":0.1443},{"period":"1year","weight":0.1619},{"period":"ytd","weight":0.1113}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Humacyte, Inc.于2020年7月1日在特拉华州注册成立。该公司是一家处于商业化阶段的生物技术平台公司，致力于以商业规模开发可普遍植入的生物工程人体组织。其主要产品Symvess是一种经美国食品药品监督管理局批准的无细胞组织工程血管，用于肢体动脉损伤时的血管导管，公司还在开发用于其他血管及非血管应用的同类产品线。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.017034},{"month":2,"riseRate":0.833333,"avgChangeRate":0.099369},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.187537},{"month":4,"riseRate":0.666667,"avgChangeRate":0.081164},{"month":5,"riseRate":0.666667,"avgChangeRate":0.349792},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.25418},{"month":7,"riseRate":0.666667,"avgChangeRate":0.194299},{"month":8,"riseRate":0.5,"avgChangeRate":-0.018547},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.097166},{"month":10,"riseRate":0.2,"avgChangeRate":-0.109563},{"month":11,"riseRate":0.4,"avgChangeRate":0.00984},{"month":12,"riseRate":0.5,"avgChangeRate":-0.123651}],"exchange":"NASDAQ","name":"Humacyte, Inc.","nameEN":"Humacyte, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Humacyte, Inc.(HUMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Humacyte, Inc.(HUMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Humacyte, Inc.,HUMA,Humacyte, Inc.股票,Humacyte, Inc.股票老虎,Humacyte, Inc.股票老虎国际,Humacyte, Inc.行情,Humacyte, Inc.股票行情,Humacyte, Inc.股价,Humacyte, Inc.股市,Humacyte, Inc.股票价格,Humacyte, Inc.股票交易,Humacyte, Inc.股票购买,Humacyte, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Humacyte, Inc.(HUMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Humacyte, Inc.(HUMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}